



下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEXL388Cat. No.: HY-13806CAS No.: 1251156-08-7分式: CHFNOS分量: 455.5作靶點: mTOR作通路: PI3K/Akt/mTOR儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 50 mg/mL (109.77 mM; Need ultrasonic)Mass Solvent1
2、mg 5 mg 10 mg Concentration制備儲備液1 mM 2.1954 mL 10.9769 mL 21.9539 mL5 mM 0.4391 mL 2.1954 mL 4.3908 mL10 mM 0.2195 mL 1.0977 mL 2.1954 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前請先配制澄清的儲備液,再依次添加助溶?為保證實驗結(jié)果的可靠性,體內(nèi)實驗的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲備液可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終
3、溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.49 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.49 mM); Clear solutionBIOLOGICAL ACTIVITY1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 XL388種效的 ATP 競爭性 mTO
4、R 抑制劑,IC50 為 9.9 nM。XL388 同時抑制 mTORC1 和 mTORC2。IC50 & Target mTOR mTORC1 mTORC2 DNA-PK9.9 nM (IC50) 8.831 M (IC50)體外研究 XL388 (Compound 28) also inhibits DNA-PK with an IC50 of 8.831 M. XL388 inhibits cellularphosphorylation of mTOR complex 1 (p-p70S6K, pS6, and p-4E-BP1) and mTOR complex 2 (pAKT (S4
5、73)substrates. XL388 acts in an ATP-competitive manner, with a linear increase in IC50 values with increasingATP concentration 1. XL388 shows a dose-dependent effect in promoting MG-63 cell apoptosis. XL388(100 nM) induces apoptosis in other two OS cell lines (U2OS and SaOs-2), but not in non-cancer
6、ous MC3T3-E1 cells. XL388 potently inhibits activation of both mTORC1 and mTORC2 in MG-63 cells. The effect ofXL388 on mTORC1/2 activation is again dose-dependent. Further, mTORC1/2 activation is almost blocked inXL388 (100 nM)-treated U2OS cells, SaOs-2 cells and primary human OS cells 2.體內(nèi)研究 To as
7、sess the pharmacodynamic effects of XL388 (Compound 28) on the mTOR pathway signaling, athymicnude mice bearing PC-3 prostate tumors are dosed orally at 100 mg/kg of XL388. Rapamycin is alsoadministered intraperitoneally at 5 mg/kg as a reference. Plasma and tumor samples are collected at 1, 4, 8,16
8、, 24, and 32 h for XL388 and at 4 h for Rapamycin after dosing and homogenized with buffer. Tumorlysates from each animal (n=5) are then pooled for each group and analyzed by immunoblot for levels ofphosphorylated p70S6K, S6, 4E-BP1, and AKT. XL388 has moderate terminal elimination half-life (t1/2=1
9、.35h, 0.45 h, 6.11 h and 0.86 h for mouse (10 mg/kg, iv), rat (3 mg/kg, iv), dog (3 mg/kg, iv), monkey (3 mg/kg,iv) 1.PROTOCOLKinase Assay 1 The measurement of mTOR enzyme activity is performed in an ELISA format following the phosphorylationof 4E-BP1 protein. All experiments are performed in the 38
10、4-well format. Generally, 0.5 L of DMSOcontaining varying concentrations of the test compound is mixed with 15 L of the enzyme solution. Kinasereactions are initiated with the addition of 15 L of a solution containing the substrate. The assay conditionsare as follows: 0.2 nM mTOR, 10 M ATP, and 50 n
11、M NHis-tagged 4E-BP1 in 20 mM Hepes, pH 7.2, 1 mMDTT, 50 mM NaCl, 10 mM MnCl2, 0.02 mg/mL BSA, 0.01% CHAPS, 50 mM -glycerophophate. Followingan incubation of 120 min at ambient temperature, 20 L of the reaction mixture is transferred to a Ni-chelate-coated 384-well plate. The binding step of the 4E-
12、BP1 protein proceeded for 60 min, followed by washingfour times each with 50 L of Tris-buffered saline solution (TBS). Anti-phospho-4E-BP1 rabbitimmunoglobulin G (IgG; 20 L, 1:5000) in 5% BSA-TBST (0.2% Tween-20 in TBS) is added, and the reactionmixuture is further incubated for 60 min. Incubation w
13、ith a secondary horseradish peroxidase (HRP)-taggedanti-IgG is similarly performed after the primary antibody is washed off (four washes of 50 L). Following thefinal wash step with TBST, 20 L of SuperSignal ELISA Femto is added and the luminescence measuredusing an EnVision plate reader. Data are re
14、ported as the mean (n2) 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 2 U2OS, SaOs-2 and MG-63 OS cell lines as well as the murine calvaria-derived osteoblastic MC3T3-E1 cellsare maintained and culture. The OB-6 human osteoblastic cells a
15、re cultured. For primary culture of murine2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEosteoblasts, the trimmed calvariae of neonatal mice are digested with 0.1% collagenase I and 0.25%dispase. The resolving cell suspensions are neutralized with complete culture medium and are filtered. Thecalva
16、rial osteoblasts are then resuspended in 10 mL -MEM containing 15% FBS, and are cultured. Cells(5104/well) are suspended in 1 mL of DMEM with 1% agar, 10 % FBS and with indicated XL388 (5, 25, 100and 200nM) treatment. The cell suspension is then added on top of a pre-solidified 1% agar in a 100 mmcu
17、lture dish. The drug containing medium is refreshed every 2 days. After 10-day incubation, the number ofremaining colonies are stained and manually counted 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice, Rats, Dogs and Monkeys 1Administra
18、tion 1 Pharmacokinetic studies of XL388 are determined in female athymic nude mice, female CD rats, male beagledogs, and male cynomolgus monkeys. XL388 is administered intravenously and by oral gavage at 10 mg/kgas a solution formulated in EPW (5% ethanol/45% PEG400/water+1:2 HCl (m/m) to mice, 3 mg
19、/kg as asolution formulated in EPW (5% ethanol/45% PEG400/water+1:2 HCl (m/m) to CD rats and male beagledogs, and 3 mg/kg as a solution formulated in EPW (5% ethanol/45% PEG400/water+1:1.5 HCl (m/m) tomale cynomolgus monkeys. The plasma levels of XL388 are monitored over a 24 h period.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Oncotarget. 2017 May 2;8(18):30151-30161. Oncotarget. 2016 Aug 2;7(31):49527-49
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 言語語言障礙兒童教育
- C語言課件知識點
- B超相關(guān)知識課件
- AT供電知識課件
- 教育心理學(xué)移情訓(xùn)練程序
- 云南省元江民中2025屆高三第六次考試數(shù)學(xué)試題試卷含解析
- 人教版數(shù)學(xué)六年級下冊期末應(yīng)用題訓(xùn)練含答案
- 河南省開封市田家炳實驗中學(xué)2024-2025學(xué)年中考英語試題模擬卷(二)含答案
- 云南民族大學(xué)《世界文化概論》2023-2024學(xué)年第二學(xué)期期末試卷
- 電商商家數(shù)據(jù)安全合作協(xié)議合同范本
- 高速鐵路知識.ppt課件
- ADAScog(老年癡呆量表—認(rèn)知)
- 藥品經(jīng)營中存在的問題及監(jiān)管對策
- ZN73A(X)永磁式戶內(nèi)中壓真空斷路器
- sch壁厚等級對照表要點
- 水利工程供水定價成本監(jiān)審辦法
- 石頭峽水電站水利樞紐工程壩體設(shè)計說明書畢業(yè)設(shè)計
- 儲罐及輸油管道拆除方案(完整版)
- 淺談石油化工建設(shè)項目的工程造價管理與控制
- 2022年2022年雷鋒叔叔你在哪里說課稿
- 中國臨床路徑-內(nèi)分泌科(5個)
評論
0/150
提交評論